Mutational landscape in genetically engineered, carcinogen-induced, and radiation-induced mouse sarcoma
Chang‐Lung Lee(Duke University), David G. Kirsch(Princess Margaret Cancer Centre), Isibel Caraballo, Alexander B. Sibley(Duke University), Kouros Owzar(Duke University), Amy J. Wisdom(Duke Medical Center), Yvonne M. Mowery(University of Pittsburgh), Joe R. Delaney(Medical University of South Carolina), Jeremy S. Gresham(Cancer Institute (WIA)), Lixia Luo(Duke Medical Center), Andrea R. Daniel(Inserm), Xi Wang(United States Food and Drug Administration), David Van Mater(Cancer Institute (WIA)), Dadong Zhang(Duke Cancer Institute), Xiaodi Qin(Duke Cancer Institute)
Cited by 60
Related Papers
Restoration of p53 function leads to tumour regression in vivo
|Nature|2007|1.8k
Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial
|The Lancet|2009|1.4k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.2k